{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:20:08Z","timestamp":1792700408912,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience &amp; Biobehavioral Reviews"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.neubiorev.2023.105185","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T04:27:48Z","timestamp":1682656068000},"page":"105185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["The effectiveness of oxytocin for treating substance use disorders:A systematic review of randomized placebo-controlled trials"],"prefix":"10.1016","volume":"151","author":[{"given":"Angelina Isabella","family":"Mellentin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Wallhed","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Sk\u00f8t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Thaysen-Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaj","family":"Mistarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Fink-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorthe Gr\u00fcner","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neubiorev.2023.105185_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.neubiorev.2023.105185_bib2","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.neubiorev.2023.105185_bib3","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105185_bib4","first-page":"237","article-title":"Dual diagnosis: coexisting substance use disorders and psychiatric disorders","volume":"51","author":"Antai-Otong","year":"2016","journal-title":"Nurs. Clin."},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105185_bib5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105185_bib6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","article-title":"An inventory for measuring clinical anxiety: psychometric properties","volume":"56","author":"Beck","year":"1988","journal-title":"J. Consult. Clin. Psychol."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105185_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0272-7358(88)90050-5","article-title":"Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation","volume":"8","author":"Beck","year":"1988","journal-title":"Clin. Psychol. Rev."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105185_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.coph.2008.12.014","article-title":"Dissecting components of reward:\u2018liking\u2019,\u2018wanting\u2019, and learning","volume":"9","author":"Berridge","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105185_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40501-014-0013-6","article-title":"Behavioral interventions and pharmacotherapies for cannabis use disorder","volume":"1","author":"Bobb","year":"2014","journal-title":"Curr. Treat. Options Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105185_bib10","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1530-0277.1995.tb01554.x","article-title":"Development and initial validation of a measure of drinking urges in abstinent alcoholics","volume":"19","author":"Bohn","year":"1995","journal-title":"Alcohol.: Clin. Exp. Res."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105185_bib11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1037\/1064-1297.9.2.183","article-title":"The cue-availability paradigm: the effects of cigarette availability on cue reactivity in smokers","volume":"9","author":"Carter","year":"2001","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105185_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0740-5472(86)90018-8","article-title":"Conditioned responses in a methadone population: a comparison of laboratory, clinic, and natural settings","volume":"3","author":"Childress","year":"1986","journal-title":"J. Subst. Abuse Treat."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105185_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14622200020032051","article-title":"Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings","volume":"3","author":"Cox","year":"2001","journal-title":"Nicotine Tob. Res."},{"issue":"12","key":"10.1016\/j.neubiorev.2023.105185_bib14","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","article-title":"The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"5","author":"Degenhardt","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105185_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bs.3830190102","article-title":"The Hopkins Symptom Checklist (HSCL): a self\u2010report symptom inventory","volume":"19","author":"Derogatis","year":"1974","journal-title":"Behav. Sci."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105185_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev-psych-122414-033457","article-title":"Drug addiction: updating actions to habits to compulsions ten years on","volume":"67","author":"Everitt","year":"2016","journal-title":"Annu Rev. Psychol."},{"key":"10.1016\/j.neubiorev.2023.105185_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2022.110561","article-title":"Peripheral oxytocin concentrations in psychiatric disorders - a systematic review and methanalysis: Further evidence","volume":"117","author":"Ferreira","year":"2022","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2023.105185_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/ijms22052372","article-title":"Oxytocin signaling as a target to block social defeat-induced increases in drug abuse reward","volume":"22","author":"Ferrer-P\u00e9rez","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.neubiorev.2023.105185_bib19","series-title":"Structured clinical interview for Axis I DSM-IV disorders","author":"First","year":"1994"},{"key":"10.1016\/j.neubiorev.2023.105185_bib20","unstructured":"First, M.B., Structured clinical interview for DSM-IV axis I disorders. Biometrics Research Department, 1997."},{"key":"10.1016\/j.neubiorev.2023.105185_bib21","series-title":"Structured clinical interview for DSM-IV-TR axis I disorders, clinical trials version (SCID-CT)","author":"First","year":"2007"},{"key":"10.1016\/j.neubiorev.2023.105185_bib22","series-title":"Structured clinical interview for DSM-5\u2014research version (SCID-5 for DSM-5, research version; SCID-5-RV)","first-page":"1","author":"First","year":"2015"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105185_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1037\/pha0000232","article-title":"Effects of oxytocin on stress reactivity and craving in veterans with co-occurring PTSD and alcohol use disorder","volume":"27","author":"Flanagan","year":"2019","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105185_bib24","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1530-0277.1999.tb04349.x","article-title":"Psychometric properties of the Penn alcohol craving scale","volume":"23","author":"Flannery","year":"1999","journal-title":"Alcohol.: Clin. Exp. Res."},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105185_bib25","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0306-4603(01)00201-5","article-title":"Initial validation of two opiate craving questionnaires: the Obsessive Compulsive Drug Use Scale and the Desires for Drug Questionnaire","volume":"27","author":"Franken","year":"2002","journal-title":"Addict.\u00a0Behav."},{"issue":"11","key":"10.1016\/j.neubiorev.2023.105185_bib26","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1176\/appi.ajp.157.11.1789","article-title":"Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli","volume":"157","author":"Garavan","year":"2000","journal-title":"Am. J. Psychiatry"},{"issue":"10292","key":"10.1016\/j.neubiorev.2023.105185_bib27","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/S0140-6736(21)01169-7","article-title":"Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990\u20132019: a systematic analysis from the Global Burden of Disease Study 2019","volume":"397","author":"GBD 2019 Tobacco Collaborators","year":"2021","journal-title":"Lancet (Lond., Engl.)"},{"key":"10.1016\/j.neubiorev.2023.105185_bib28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.neubiorev.2021.02.006","article-title":"Consistency between self-reported alcohol consumption and biological markers among patients with alcohol use disorder - a systematic review","volume":"124","author":"Gr\u00fcner Nielsen","year":"2021","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.neubiorev.2023.105185_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105185_bib30","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1176\/appi.ajp.2013.12060782","article-title":"DSM-5 criteria for substance use disorders: recommendations and rationale","volume":"170","author":"Hasin","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.neubiorev.2023.105185_bib31","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","article-title":"The Fagerstr\u00f6m test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire","volume":"86","author":"Heatherton","year":"1991","journal-title":"Br. J. Addict."},{"issue":"1\u20133","key":"10.1016\/j.neubiorev.2023.105185_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.drugalcdep.2008.12.010","article-title":"Reliability and validity of a short form of the Marijuana Craving Questionnaire","volume":"102","author":"Heishman","year":"2009","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105185_bib33","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/14622200801908174","article-title":"Reliability and validity of a short form of the tobacco craving questionnaire","volume":"10","author":"Heishman","year":"2008","journal-title":"Nicotine Tob. Res."},{"issue":"21","key":"10.1016\/j.neubiorev.2023.105185_bib34","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1111\/bph.15617","article-title":"Can intranasal oxytocin reduce craving in automated addictive behaviours? A systematic review","volume":"178","author":"Houghton","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.neubiorev.2023.105185_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.146761","article-title":"The role of oxytocin in alcohol and drug abuse","volume":"1736","author":"King","year":"2020","journal-title":"Brain Res"},{"issue":"1\u20132","key":"10.1016\/j.neubiorev.2023.105185_bib36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000119004","article-title":"The \u2018Trier Social Stress Test\u2019\u2013a tool for investigating psychobiological stress responses in a laboratory setting","volume":"28","author":"Kirschbaum","year":"1993","journal-title":"Neuropsychobiology"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105185_bib37","first-page":"127","article-title":"Oxytocin: the great facilitator of life","volume":"88","author":"Lee","year":"2009","journal-title":"Prog. Neurobiol."},{"issue":"9","key":"10.1016\/j.neubiorev.2023.105185_bib38","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.euroneuro.2014.06.005","article-title":"Complexity of oxytocin\u05f3s effects in a chronic cocaine dependent population","volume":"24","author":"Lee","year":"2014","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105185_bib39","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/FBP.0000000000000258","article-title":"Oxytocin for the treatment of drug and alcohol use disorders","volume":"27","author":"Lee","year":"2016","journal-title":"Behav. Pharm."},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105185_bib40","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.addbeh.2004.02.062","article-title":"Deficits in plasma oxytocin responses and increased negative affect, stress, and blood pressure in mothers with cocaine exposure during pregnancy","volume":"29","author":"Light","year":"2004","journal-title":"Addict. Behav."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105185_bib41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000371637","article-title":"Association between blood level of plasma oxytocin and novelty seeking among methadone-maintained heroin users","volume":"71","author":"Lin","year":"2015","journal-title":"Neuropsychobiology"},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105185_bib42","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.psyneuen.2011.02.015","article-title":"A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research","volume":"36","author":"MacDonald","year":"2011","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105185_bib43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1037\/1064-1297.16.1.57","article-title":"Further validation of a cigarette purchase task for assessing the relative reinforcing efficacy of nicotine in college smokers","volume":"16","author":"MacKillop","year":"2008","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105185_bib44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1037\/1064-1297.13.3.229","article-title":"Reactivity to alcohol cues: isolating the role of perceived availability","volume":"13","author":"MacKillop","year":"2005","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105185_bib45","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00213-019-05392-z","article-title":"The influence of gender and oxytocin on stress reactivity, cigarette craving, and smoking in a randomized, placebo-controlled laboratory relapse paradigm","volume":"237","author":"McClure","year":"2020","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105185_bib46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1369-1600.2008.00135.x","article-title":"Developing human laboratory models of smoking lapse behavior for medication screening","volume":"14","author":"McKee","year":"2009","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neubiorev.2023.105185_bib47","unstructured":"McNair, D.M., M. Lorr, and L.F. Droppleman, Manual profile of mood states. 1971."},{"key":"10.1016\/j.neubiorev.2023.105185_bib48","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00213-013-3062-4","article-title":"Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study","volume":"228","author":"McRae-Clark","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neubiorev.2023.105185_bib49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.01.003","article-title":"Effect of intranasal oxytocin on alcohol withdrawal syndrome: a randomized placebo-controlled double-blind clinical trial","volume":"197","author":"Melby","year":"2019","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105185_bib50","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/alcalc\/agaa133","article-title":"Efficacy of self-administered intranasal oxytocin on alcohol use and craving after detoxification in patients with alcohol dependence. a double-blind placebo-controlled trial","volume":"56","author":"Melby","year":"2020","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.neubiorev.2023.105185_bib51","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.psychres.2017.02.067","article-title":"Substance abuse in patients with bipolar disorder: a systematic review and meta-analysis","volume":"253","author":"Messer","year":"2017","journal-title":"Psychiatry Res"},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105185_bib52","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/FBP.0000000000000260","article-title":"Intranasal oxytocin dampens cue-elicited cigarette craving in daily smokers: a pilot study","volume":"27","author":"Miller","year":"2016","journal-title":"Behav. Pharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105185_bib53","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/ADM.0000000000000213","article-title":"Intranasal oxytocin selectively modulates social perception, craving, and approach behavior in subjects with alcohol use disorder","volume":"10","author":"Mitchell","year":"2016","journal-title":"J. Addict. Med"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105185_bib54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000496194","article-title":"The effects of oxytocin on withdrawal, craving and stress response in heroin-dependent patients: a randomized, double-blind clinical trial","volume":"25","author":"Moeini","year":"2019","journal-title":"Eur. Addict. Res"},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105185_bib55","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105185_bib56","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/YCO.0000000000000510","article-title":"Treatment of substance use disorders with co-occurring severe mental health disorders","volume":"32","author":"Murthy","year":"2019","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.neubiorev.2023.105185_bib57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5812\/ijpbs.104627","article-title":"Oxytocin blocks opioid withdrawal symptoms only when combined with group therapy: a double-blind, randomized controlled clinical trial","volume":"14","author":"Naderi","year":"2020","journal-title":"Iran. J. Psychiatry Behav. Sci."},{"key":"10.1016\/j.neubiorev.2023.105185_bib58","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.addbeh.2014.11.020","article-title":"On the invariance of the Stimulant Craving Questionnaire (STCQ) across cocaine and methamphetamine users","volume":"42","author":"Northrup","year":"2015","journal-title":"Addict. Behav."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105185_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105185_bib60","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/add.13974","article-title":"Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate","volume":"113","author":"Palpacuer","year":"2018","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105185_bib61","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1530-0277.2012.01958.x","article-title":"Intranasal oxytocin blocks alcohol withdrawal in human subjects","volume":"37","author":"Pedersen","year":"2013","journal-title":"Alcohol Clin. Exp. Res"},{"key":"10.1016\/j.neubiorev.2023.105185_bib62","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neubiorev.2020.04.023","article-title":"Exogenous effects of oxytocin in five psychiatric disorders: a systematic review, meta-analyses and a personalized approach through the lens of the social salience hypothesis","volume":"114","author":"Peled-Avron","year":"2020","journal-title":"Neurosci. Biobehav Rev."},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105185_bib63","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1530-0277.2007.00345.x","article-title":"Multidimensionality of the alcohol withdrawal symptom checklist: a factor analysis of the alcohol withdrawal symptom checklist and CIWA\u2010Ar","volume":"31","author":"Pittman","year":"2007","journal-title":"Alcohol.: Clin. Exp. Res."},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105185_bib64","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/eurpub\/ckz064","article-title":"Trends in substance use and in the attributable burden of disease and mortality in the WHO European region, 2010\u201316","volume":"29","author":"Rehm","year":"2019","journal-title":"Eur. J. Public Health"},{"issue":"23","key":"10.1016\/j.neubiorev.2023.105185_bib65","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.3390\/jcm10235696","article-title":"Beta-endorphin and oxytocin in patients with alcohol use disorder and comorbid depression","volume":"10","author":"Roschina","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.neubiorev.2023.105185_bib66","series-title":"Mini neuropsychiatric international interview 7.0 (MINI 7.0)","author":"Sheehan","year":"2015"},{"key":"10.1016\/j.neubiorev.2023.105185_bib67","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59 Suppl 20","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neubiorev.2023.105185_bib68","first-page":"249","article-title":"Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention","author":"Sherman","year":"2017","journal-title":"Psychiatry Res."},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105185_bib69","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/phar.1747","article-title":"Treatment of cannabis use disorder: current science and future outlook","volume":"36","author":"Sherman","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105185_bib70","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40263-020-00711-x","article-title":"Pharmacological treatment of methamphetamine\/amphetamine dependence: a systematic review","volume":"34","author":"Siefried","year":"2020","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105185_bib71","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/acer.13325","article-title":"No wrong doors: findings from a critical review of behavioral randomized clinical trials for individuals with co\u2010occurring alcohol\/drug problems and posttraumatic stress disorder","volume":"41","author":"Simpson","year":"2017","journal-title":"Alcohol.: Clin. Exp. Res."},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105185_bib72","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1360-0443.1988.tb00485.x","article-title":"Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations","volume":"83","author":"Sobell","year":"1988","journal-title":"Br. J. Addict."},{"key":"10.1016\/j.neubiorev.2023.105185_bib73","article-title":"Manual for the state-trait anxietry, inventory","author":"Spielberger","year":"1970","journal-title":"Consult. Psychol."},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105185_bib74","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3109\/16066359.2016.1173682","article-title":"A two-week pilot study of intranasal oxytocin for cocaine-dependent individuals receiving methadone maintenance treatment for opioid use disorder","volume":"24","author":"Stauffer","year":"2016","journal-title":"Addict. Res Theory"},{"issue":"12","key":"10.1016\/j.neubiorev.2023.105185_bib75","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1111\/acer.14217","article-title":"Effects of oxytocin administration on cue-induced craving in co-occurring alcohol use disorder and PTSD: a within-participant randomized clinical trial","volume":"43","author":"Stauffer","year":"2019","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.neubiorev.2023.105185_bib76","article-title":"Intranasal oxytocin for stimulant use disorder among male veterans enrolled in an opioid treatment program: a randomized controlled trial","volume":"12","author":"Stauffer","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.neubiorev.2023.105185_bib77","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105185_bib78","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002130000637","article-title":"Effects of buprenorphine\/naloxone in opioid-dependent humans","volume":"154","author":"Stoller","year":"2001","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.neubiorev.2023.105185_bib79","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA\u2010Ar)","volume":"84","author":"Sullivan","year":"1989","journal-title":"Br. J. Addict."},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105185_bib80","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s00213-020-05563-3","article-title":"Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis","volume":"237","author":"Tardelli","year":"2020","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105185_bib81","article-title":"Maternal plasma levels of oxytocin during breastfeeding-A systematic review","volume":"15","author":"Uvn\u00e4s Moberg","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105185_bib82","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/ntr\/nty080","article-title":"Oxytocin reduces cigarette consumption in daily smokers","volume":"21","author":"Van Hedger","year":"2019","journal-title":"Nicotine Tob. Res"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105185_bib83","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ntr\/nty159","article-title":"Effects of intranasal oxytocin on stress-induced cigarette craving in daily smokers","volume":"22","author":"Van Hedger","year":"2020","journal-title":"Nicotine Tob. Res"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105185_bib84","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The clinical opiate withdrawal scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J. Psychoact. Drugs"},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105185_bib85","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/nur.4770130405","article-title":"A critical review of visual analogue scales in the measurement of clinical phenomena","volume":"13","author":"Wewers","year":"1990","journal-title":"Res. Nurs. Health"},{"issue":"13","key":"10.1016\/j.neubiorev.2023.105185_bib86","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s00213-016-4308-8","article-title":"The effects of intranasal oxytocin in opioid-dependent individuals and healthy control subjects: a pilot study","volume":"233","author":"Woolley","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neubiorev.2023.105185_bib87","series-title":"The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines","author":"World Health Organization","year":"1992"}],"container-title":["Neuroscience &amp; Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763423001549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763423001549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:33:45Z","timestamp":1758969225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763423001549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":87,"alternative-id":["S0149763423001549"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105185","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effectiveness of oxytocin for treating substance use disorders:A systematic review of randomized placebo-controlled trials","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105185"}}